30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

UBS Oncology Impact Fund L.P.

Track

Insider profile

Performance

Overall performance
2.3
Performance over holding periods
2.3
30 days 90 days 120 days
Average return 15% 8.2% 15.1%
Success rate 74% 68% 82%
Transactions
3 67% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
UBS Oncology Impact Fund L.P.'s trades of Werewolf Therapeutics Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-28 2026-05-28
PrS Proposed sale
8,424
36.26
US$4,295,767 		8,424 36.26 US$4,295,767
2026-05-18 2026-05-18
PrS Proposed sale
42,168
410.57
US$4,458,262 		42,168 410.57 US$4,458,262
2026-05-11 2026-05-11
PrS Proposed sale
18,030
114.45
US$3,516,802 		18,030 114.45 US$3,516,802
2026-05-01 2026-05-01
PrS Proposed sale
300,821
0.72
US$216,471 		300,821 0.72 US$216,471
2026-04-29 2026-04-29
PrS Proposed sale
107,652
0.74
US$79,662 		107,652 0.74 US$79,662
2026-04-27 2026-04-27
PrS Proposed sale
107,652
0.81
US$87,521 		107,652 0.81 US$87,521
2026-01-06 2026-01-06
PrS Proposed sale
164,126
0.64
US$105,763 		164,126 0.64 US$105,763
2025-12-29 2025-12-29
PrS Proposed sale
107,463
0.65
US$70,313 		107,463 0.65 US$70,313
2025-12-22 2025-12-22
PrS Proposed sale
107,463
0.69
US$73,806 		107,463 0.69 US$73,806
2025-12-10 2025-12-10
PrS Proposed sale
73,195
1.01
US$73,927 		73,195 1.01 US$73,927
2025-12-03 2025-12-03
PrS Proposed sale
107,463
0.86
US$92,418 		107,463 0.86 US$92,418
2025-11-24 2025-11-24
PrS Proposed sale
107,463
0.87
US$93,837 		107,463 0.87 US$93,837
2025-11-17 2025-11-17
PrS Proposed sale
107,463
0.92
US$98,673 		107,463 0.92 US$98,673
2025-11-10 2025-11-10
PrS Proposed sale
107,463
1.15
US$123,582 		107,463 1.15 US$123,582
2025-11-04 2025-11-04
PrS Proposed sale
107,463
1.31
US$140,777 		107,463 1.31 US$140,777
2025-10-30 2025-10-30
PrS Proposed sale
107,463
1.56
US$167,642 		107,463 1.56 US$167,642
2025-10-27 2025-10-27
PrS Proposed sale
107,463
1.77
US$190,210 		107,463 1.77 US$190,210
2021-09-13 2021-09-13
PlS Planned sale
3,595 -0.0%
29.10
US$104,614 		3,595 -0.0% 29.10 US$104,614
2021-09-13 2021-09-10
PlS Planned sale
5,931 -0.1%
29.04
US$172,236 		5,931 -0.1% 29.04 US$172,236
2021-09-13 2021-09-09
PlS Planned sale
13,727 -0.2%
29.35
US$402,887 		13,727 -0.2% 29.35 US$402,887
2021-01-14 2021-01-12
B Purchase
300,000 +3.9%
21.00
US$6,300,000 		300,000 +3.9% 21.00 US$6,300,000
2020-10-08 2020-10-06
US Oncorus Inc (ONCR)
B Purchase
151,224 +6.8%
15.00
US$2,268,360 		151,224 +6.8% 15.00 US$2,268,360
2019-02-21 2019-02-19
B Purchase
666,667 +24.7%
15.00
US$10,000,005 		666,667 +24.7% 15.00 US$10,000,005
2019-02-14 2019-02-12
B Purchase
250,000 +6.9%
14.00
US$3,500,000 		250,000 +6.9% 14.00 US$3,500,000
2019-02-14 2019-02-12
S Sale
447 -0.0%
14.00
US$6,258 		447 -0.0% 14.00 US$6,258